Epiomic Epidemiology Report: Friedreich’s Ataxia Forecast In 28 Major Markets 2018-2028 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Sep 19, 2018--The “Epiomic Epidemiology Series: Friedreich’s Ataxia Forecast In 28 Major Markets 2018-2028” report has been added to ResearchAndMarkets.com’s offering.
Friedreich’s ataxia (FA) is a rare genetic neurodegenerative disorder with the majority of cases involving expansion of a trinucleotide sequence in the gene coding for the protein fraxatin. Symptoms usually appear during childhood or adolescence as unsteadiness of gait which progresses into inability to walk independently within a few years, alongside other signs and symptoms. There are also cases of late-onset FA in which symptoms appear in middle age. Untreated FA results in limited life expectancy with death occurring due to multisystem complications and trauma sequelae, although the current therapies have significantly improved the average survival of FA patients.
This report provides the current prevalent population for FA across 28 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Belgium, Norway, Sweden, Denmark, Finland, Austria, Switzerland, Ireland, Greece, Russia, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. In addition to the current prevalence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the publisher’s analysis team, FA patients grouped by genetic features and symptoms have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities of FA include:Left ventricular hypertrophy Supraventricular tachycardias Diabetes Scoliosis Cognitive deficits Affective disorders
Key Topics Covered:List Of Tables And Figures Introduction Cause Of The Disease Risk Factors & Prevention Diagnosis Of The Disease Variation By Geography/Ethnicity Disease Prognosis & Clinical Course Key Comorbid Conditions / Features Associated With The Disease Methodology For Quantification Of Patient Numbers Top-Line Prevalence For Friedreich’S Ataxia Features Of Friedreich’S Ataxia Patients Signs And Symptoms Of Friedreich’S Ataxia Patients Comorbidities Of Friedreich’S Ataxia Patients Abbreviations Used In The Report Other Publisher Services & Solutions Reports & Publications Online Epidemiology Databases Online Pharmaceutical Pricing Database References Appendix For more information about this report visit https://www.researchandmarkets.com/research/z4bs8w/epiomic?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180919005604/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Central Nervous System Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/19/2018 12:24 PM/DISC: 09/19/2018 12:24 PM